Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | GALR3 | O60755 | 2/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341524 | 0.86 | RAB9A (0.64) | RAB9AHTTSMN1; SMN2MAPTTHRB | |
| SCHEMBL3342180 | 0.83 | HTT (0.60) | RAB9AHTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL3342307 | 0.82 | RAB9A (0.58) | RAB9AHTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL5463611 | 0.80 | MAPT (0.62) | HTTMAPTLMNATP53POLB | |
| Hydrochloric Acid SCHEMBL5474323 | 0.79 | MAPT (0.61) | HTTMAPTLMNATP53POLB | |
| SCHEMBL8497061 | 0.77 | RAB9A (0.64) | RAB9AHTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL3339732 | 0.77 | RAB9A (0.66) | RAB9AHTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL3339804 | 0.77 | MEN1 (0.64) | RAB9AHTTSMN1; SMN2MAPTLMNA | |
| SCHEMBL3342319 | 0.76 | CCNC (0.70) | RAB9AHTTSMN1; SMN2MAPTTHRB | |
| SCHEMBL3339911 | 0.76 | TNF (0.65) | RAB9AHTTSMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | RAB9A 2578/4885HTT 383/4885SMN1; SMN2 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.